SINGAPORE, Dec. 19, 2025 /PRNewswire/ — DomoAI, a complete AI animation platform for video generation and creation workflow focused, has released a paired update that integrates AI image editing with keyframe-based video generation, enabling users to convert still images into animated videos within a single workflow.

The update combines Nano Banana Pro, an AI image editor offering unlimited image generation for subscribed users, with Frames to Video, a tool that transforms two to eight images into short animated clips using text prompts.

Nano Banana Pro allows users to edit and refine multiple images before animation, adjusting composition, style, and visual details. Frames to Video supports two creation modes, generating three-to-eight-second clips from two images or longer sequences using multiple keyframes with custom timing. Visual consistency is maintained across frames, and outputs are delivered as high-resolution MP4 files.

The combined workflow supports applications including social content creation, product visuals, creative prototyping, and personal projects. Users can access both features directly through a browser.

To mark the launch, DomoAI is offering 15% off all subscription plans with nano banana pro unlimited generation through January 2.

For media inquiries, please contact:

Public Relations

Email: marketing@domoai.app

SINGAPORE, Dec. 19, 2025 /PRNewswire/ — Galatek, a fast-growing Singapore-based automation and artificial intelligence (AI) startup, announced today that it has secured approximately US$30 million in Series A funding. The funding will accelerate the company’s development of innovative products in life sciences and advanced semiconductor manufacturing, strengthen its global supply chain, and deepen local expertise in key markets across Europe, North America, and Southeast Asia.

As AI continues to accelerate digital transformation across industries, Galatek addresses critical challenges in life sciences and semiconductor manufacturing. The company provides automation and AI solutions that are reshaping smart labs and advanced packaging – key sectors where precision and intelligence define the next generation of innovation. Based in Singapore’s innovation hub, Galatek combines its agile, globally-connected R&D with localized commercial presence in strategic markets, positioning itself as an essential enabler of industrial progress in the AI era.

Galatek is strategically focused on two high-demand market areas where significant technology gaps remain:

In Life Sciences

The company is pioneering the smart laboratory of the future. By deeply integrating AI into R&D and service workflows, Galatek empowers scientists to accelerate and de-risk discovery across complex applications, including diagnostics, NGS sequencing, 3D cell & organoid culture, drug development, and synthetic biology. This is further enhanced through Galatek’s Abio software platform, an integrated AI-driven solution that unifies ELN, LIMS, SDMS and advanced automation to transform scientific data into actionable insights, streamline robotic integrations, and support customizable, cloud-agnostic smart lab operations through its extensible architecture. Galatek has forged strategic partnerships with top-tier global pharmaceutical firms and research institutions and has co-created next-generation smart labs with world-renowned academic partners like the National University of Singapore, building a pipeline for sustained technology leadership.

In Semiconductors

Galatek is also focused on AI-driven innovation and implementation for advanced packaging. With deep integration of vision AI and motion control algorithms, it is meeting extreme demands for precision and reliability. The company provides critical process equipment and solutions ranging from front-end metrology and inspection to back-end advanced packaging. Core solutions include fully automated overlay measurement systems, deep learning-based automatic optical inspection (AOI) systems, and precision wafer dicing equipment. Galatek is currently collaborating with several leading global semiconductor manufacturers, demonstrating end-to-end commercialization capabilities from technology breakthrough to scaled delivery.

Galatek’s business model, “Global Supply Chain + Localized Service,” combines the competitive advantages of Asian supply chains with company-owned delivery centers in Malaysia and the United States, creating a resilient global logistics network. In key markets, local teams in Europe, North America, and Southeast Asia provide proactive, customized support across the entire customer journey, from sales and technical service to compliance, ensuring clients receive a seamlessly integrated offering.

“The global industry is undergoing a fundamental transformation, driven by artificial intelligence and automation,” said David Tian, CEO of Galatek. “The need for smart laboratories in life sciences and the innovation imperative in semiconductor advanced packaging are not just sector-specific needs – these are critical junctures where we are focused. Galatek’s mission is to be a reliable infrastructure partner in this transformation. By combining world-class supply chain capabilities with local resources, we are confident in delivering the innovative solutions that global clients need – solutions that are often difficult for traditional providers to deploy rapidly. This Series A funding accelerates our journey to fulfill that role at scale.” 

NANJING, China and GAITHERSBURG, Md., Dec. 19, 2025 /PRNewswire/ — TransThera Sciences Nanjing, Inc. (the “TransThera”) announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation (“CDE“)of the National Medical Products Administration (“NMPA“) of the PRC. It is intended for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib tablets have been included in the List of Products for Priority Review and the List of Breakthrough Therapy Designation for this indication.

Disclaimer: This article serves as a press release by TransThera to disclose the company’s latest developments. It is not intended as a product promotion advertisement and does not constitute the company’s investment advice.

About Tinengotinib

Tinengotinib is an internally discovered, NDA stage, multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs and VEGFRs, mitotic kinases Aurora A/B and Janus kinases (JAK). Ongoing clinical trials conducted globally have revealed the potential of tinengotinib to be efficacious in various solid tumors, such as cholangiocarcinoma, prostate cancer, breast cancer, and liver cancer. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA, the Orphan Drug Designation (ODD) for the treatment of biliary tract cancer by the European Medicines Agency (EMA), the Priority Review and Approval Procedure and the Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) in China for the treatment of CCA.

About TransThera

TransThera is a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. For more information, please visit www.transthera.com.

SEOUL, South Korea, Dec. 19, 2025 /PRNewswire/ — Natural Good Things (NGT), a women’s inner-care brand, has partnered with JOGUMAN—an IP managed globally by IPX (formerly LINE FRIENDS)—to launch its new wellness campaign, “Small but Healthy.” Through the meeting, NGT has introduced four special-edition products.

NGT is a wellness brand equipped with its own R&D capabilities and ingredient manufacturing system, producing and distributing health-functional raw materials in-house. The brand has grown by focusing on products that support women’s daily health routines. Its flagship product, Saengsaeng Enzyme, has surpassed 100 million cumulative sachet sales, demonstrating strong consumer trust.

Launched in August 2025, the campaign combines JOGUMAN’s signature theme of the small yet precious joys of life with NGT’s message of “small but consistent health habits.” NGT redesigned the packaging of its popular products, Saengsaeng Enzyme, in JOGUMAN’s themed style, and added two new items: It’s Cranberry Probiotics and Saengsaeng Enzyme The Peanut, completing the four-product special edition lineup.

The products launched across Korean online channels including NGT’s official mall, Naver Smart Store, and group-buying platforms. They have since expanded into Olive Young’s online mall, strengthening the brand’s distribution footprint. Campaign creatives have been unified across all digital touchpoints—including NGT’s website, social channels, and product detail pages—to reinforce consistent brand messaging.

To commemorate the featuring JOGUMAN, NGT also released exclusive products such as four types of JOGUMAN acrylic keyrings, a JOGUMAN BRACHIO pouch keyring, and a JOGUMAN 30-Day Routine Calendar. The brand is further enhancing consumer engagement through a 30-day routine challenge and reward events.

An NGT spokesperson stated that meeting with JOGUMAN—an IP developed through IPX’s global business—has enabled us to strengthen our connection with the MZ generation and communicate NGT’s ‘healthy routine’ message with greater emotional resonance. By combining proven product quality—validated through 100 million packs sold—with the positive image of the dinosaur character JOGUMAN, we aim to offer customers a healthful yet delightful experience.

Building on the “Small but Healthy” campaign, NGT plans to continue releasing diverse content and consumer programs. In the short term, the brand will expand its customer touchpoints beyond digital channels into offline pop-ups and festivals. Long-term, NGT aims to solidify its position as a leading brand supporting sustainable health routines for women, focusing on innovative product development and enriched wellness experiences.